

Chapter 18

Influence of Exogenous IL-12 on Human Periodontal Ligament Cells

Benjar Issaranggun Na Ayuthaya and Prasit Pavasant

Abstract Periodontal disease is the most prevalent oral disease. The pathogenesis of this disease is mostly due to the robust host immune response, leading to the destruction of tooth-supporting tissue. Several cytokines have been shown to play roles in pathogenesis of periodontal disease; however, inflammatory cytokines can also activate the immunomodulatory properties of mesenchymal stem cells (MSCs), the mechanism to protect and maintain cell survival under inflammatory environment. Therefore, inflammation can exert both negative and positive effects for regulating tissue homeostasis. Interleukin 12 (IL-12) is one of the potent destructive stimulators in pathogenesis of many inflammatory diseases. In periodontitis, the increased level of IL-12 in serum and gingival crevicular fluid was found associated with the severity of the periodontal disease. However, the exact role of IL-12 in periodontitis is still unclear. The aim of this study was to investigate the responses of human periodontal ligament (PDL) cells to exogenous IL-12, especially on the immunomodulatory effects of IL-12. The results demonstrated the presence of IL-12 and IL-12 receptor (IL-12R) in periodontal tissues, and the expression was enhanced in tissues from periodontitis patients. Exogenous IL-12 stimulated the expression of some inflammatory cytokines as well as the immunomodulatory molecules, such as interferon gamma (IFN γ), human leukocyte antigen (HLA), and indoleamine-pyrrole-2,3-dioxygenase (IDO) enzyme. In conclusion, the data suggested the influence of increased IL-12, during periodontal inflammation, on controlling tissue's homeostasis by upregulating the inflammatory cytokines and modulating the function of immune cells through the expression of immunosuppressive molecules.

Keywords Interleukin 12 • Immunomodulation • Periodontal ligament cell • Interferon gamma (IFN γ) • Indoleamine-pyrrole-2,3-dioxygenase (IDO) • Human leukocyte antigen (HLA)

B. Issaranggun Na Ayuthaya • P. Pavasant (✉)
Research Unit of Mineralized Tissue, Faculty of Dentistry, Chulalongkorn University,
34 Henri-Dunant road, Pathumwan, Bangkok 10330, Thailand
e-mail: prasit215@gmail.com

18.1 Introduction

Periodontitis or periodontal disease is one of the most prevalent chronic inflammatory diseases involved in periodontium destruction. The plaque microorganism is the cause of the periodontal disease formation; however, the presence of pathogen alone is not sufficient to trigger the onset of periodontitis. Indeed, the recognition of this pathogen by host immune cells is an essential process in the pathogenesis of periodontal disease [1].

One of the critical recognition components of the host immune response to the pathogenic microorganisms and their products is a family of toll-like receptors (TLRs). The most common TLRs implicated as potent receptors for pathogen-associated periodontitis are TLR-2 and TLR-4 [2, 3]. TLR activation stimulates an intracellular signaling cascade that leads to the activation of transcription factors, such as nuclear factor- κ B (NF- κ B) and activator protein-1 (AP-1) [4]. Subsequently, the production of pro-inflammatory cytokines that play roles in the induction of osteoclastogenesis leading to bone resorption occurs. Attempts to reduce inflammation could decrease the progression and severity of bone resorption, indicating the importance of inflammatory process in pathogenesis of periodontal disease [5].

The activation of host immune response required antigen-presenting cells (APCs) such as dendritic cells (DCs) to recognize the pathogens and stimulate the adaptive immune response [6–8]. During periodontal inflammation, the increased number of DCs was found related to the severity of inflammation [8]. It has been shown that, at the initiation stage of periodontal inflammation, most of DCs resided in gingival epithelium. However, at the later stage, they moved into the periodontal tissue and activated the differentiation of adaptive immune cells [8, 9].

Interleukin 12 (IL-12) is a potent cytokine that plays an important role in immune response by driving the differentiation of naïve T cells to T helper 1 (Th1) cells and mediating long-term protection against the pathogen [10, 11]. IL-12 is mainly produced by DCs as a result of the induction by antigenic signals, particularly lipopolysaccharide (LPS), and activated T cell signals [12]. Moreover, IL-12 production is further regulated by other cytokines such as interleukin 1beta (IL-1 β), a potent osteolytic cytokine [13, 14]. These findings are concordant with the reports from many studies that the level of IL-12 was upregulated and associated with severity of inflammatory diseases [15–17].

IL-12 has been implicated as a potent destructive stimulator in the pathogenesis of several inflammatory diseases that lead to bone destruction [1, 18, 19]. The accumulation of inflammatory cytokines influences bone remodeling by alternating osteoblast and osteoclast activities. In an *in vivo* study, the injection of exogenous IL-12 resulted in the aggressive joint inflammation [20]. These evidences implicated the destructive role of IL-12 as a trigger of the inflammatory-induced bone destruction.

Although inflammation usually promotes tissue destruction, some inflammatory cytokines can activate immunomodulatory properties of MSCs, a negative mechanism that modulate host immune response. Immunomodulation is an important

property of MSCs to promote cell survival under inflammatory environment, since MSCs are susceptible to be destroyed by activated T cells and NK cells [21]. The immunomodulatory property of MSCs occurred via the upregulation of immunosuppressive molecules such as human leukocyte antigen (HLA) molecules [22, 23] and indoleamine-pyrrole 2,3-dioxygenase (IDO) enzyme [23–25]. HLA molecules attenuate immune cells' activity by signaling via their specific inhibitory receptors [26], while IDO enzyme inhibits immune response by degrading tryptophan, an essential amino acid required for T cell growth, resulted in a decrease of T cell proliferation [24]. Therefore, the function of IL-12 may involve in the moderation of host immune response and control survival and function of periodontal ligament cells.

In this study, the presences of IL-12 and IL-12R were detected in all dental tissues. The responses of hPDL cells to IL-12, regarding the expression of immunomodulatory molecules, were investigated. The function of IL-12 in hPDL cells will provide more information toward the understanding of pathogenesis of periodontal disease.

18.2 Materials and Methods

18.2.1 Cell Culture

All experimental protocols were approved by the Ethics Committee of the Faculty of Dentistry, Chulalongkorn University. Non-carious third molars extracted for orthodontic reason were collected for periodontal ligament (PDL) cell isolation as previously described [27]. Cells were cultured in standard medium (Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum with L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 mg/ml), and amphotericin B (5 mg/ml)) and incubated at 37 °C in a humidified atmosphere of 5% CO₂ in air. After the cells reached confluency, they were subcultured at a 1:3 ratio. Cells from the third to fifth passages were used in the experiments. Cell established from at least three different donors were used in each study.

18.2.2 Application of IL-12, IFN γ , IL-1 β , and TNF α

Human PDL cells were seeded in 12-well plates (2×10^5 cells/well) for 24 h and then treated with recombinant human IL-12 (p70) (0–10 ng/ml) (Peprotech, Rocky Hill, NJ), recombinant human interferon gamma (IFN γ) (1 ng/ml) (ImmunoTools, Friesoythe, Germany), recombinant human IL-1 β (1 ng/ml) (R&D System, Minneapolis, USA), or human recombinant TNF α (1 ng/ml) (Millipore, Darmstadt, Germany) for 1 day. In some experiments, 50 μ M of lisofylline (STAT4 inhibitor)

(Cayman chemical, Ann Arbor, MI, USA) or 10 μ M of NF- κ B inhibitor (Millipore) was added into the culture medium 30 min prior to the IL-12 treatment.

18.2.3 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Trizol reagent (Molecular Research Center, Cincinnati, OH) was used for total cellular RNA extraction. Total amount of RNA was quantified using a NanoDrop 2000 Spectrophotometer (Thermo Scientific, Wilmington, DE). One microgram of total RNA per sample was converted to complementary DNA by reverse transcriptase (Promega, Madison, WI). Subsequently, polymerase chain reactions (PCR) were performed with specific primers for IL-12R β_2 , IL-1 β , TNF α , and GAPDH. The sequences of used primers were GAPDH (NM002046.3), forward 5' (TGAAGGTCGGAGTCAACGGAT-3'), reverse 5' (TCACACCCATGACGAACATGG-3'); IL-12R β_2 (NC018912.2), forward 5' (CAGCACATCTCCCTTTCTGTTTTTC-3'), reverse 5' (ACTTTAAGGCTTGAAGCCTCACC-3'); IL-1 β (NM000576.2), forward 5' (GGAGCAACAAGTGGTGTCT-3'), reverse 5' (AAAGTCCAGGCTATAGCCGT-3'); and TNF α (NM000594.2), forward 5' (AAGCCTGTAGCCCATGTTGT-3'), reverse 5' (CAGATAGATGGGCTCATACC-3'). Conventional PCR was performed using Taq polymerase (Taq DNA Polymerase, Invitrogen, Brazil) in a DNA thermal cycler (BiometraGmH, Göttingen, Germany). The products were electrophoresed on a 2% agarose gel and visualized using ethidium bromide (EtBr; Bio-Rad, Hercules, CA) fluorostaining.

18.2.4 Real-Time Polymerase Chain Reaction (Real-Time PCR)

Real-time PCR was performed in a MJ Mini™ Thermal Cycler (Bio-Rad) using the LightCycler 480 SYBR Green I Master kit (Roche diagnostic) according to the manufacturer's specifications. Gene expression levels were normalized to the GAPDH expression. Then relative gene expression was calculated by CFX Manager™ software (Bio-Rad). The results were shown as fold-change values relative to the control group. The sequence of primers used in the experiment was shown in Table 18.1.

Table 18.1 Primer sequence for real-time PCR

Primer	Forward/ reverse	Sequence (5'-3')	Sequence ID
qGAPDH	F	CACTGCCAACGTGTCAGTGGTG	NM_002046.4
	R	GTAGCCCAGGATGCCCTTGAG	
IDO	F	CAT CTG CAA ATC GTG ACT AAG	NG_028155.1
	R	GTT GGG TTA CAT TAA CCT TCC TT	
HLA-G	F	GCT GTG ATC ACT GGA GCT GT	NM_002127.5
	R	ACT CTT GCC TCT CAG TCC CA	
HLA-A	F	AAG AGG AGA CAC GGA ACA CC	NM_001242758.1
	R	TCG CAG CCA ATC ATC CAC TG	

18.2.5 Statistical Analyses

Data were reported as mean \pm standard deviation (SD). Statistical significance was assessed by the Kruskal-Wallis test. The differences at $p < 0.05$ were considered as a statistical significant difference.

18.3 Results and Discussions

18.3.1 Expressions of IL-12 and IL-12 Receptor in Periodontal Tissue Increased During Periodontal Inflammation

The results in Fig. 18.1a showed the expression of IL-12 and IL-12 receptor (IL-12R) in dental tissues. Total RNA was extracted from healthy gingiva (Gin), periodontal ligament (PDL), and dental pulp (Pulp) and subjected to RT-PCR analysis. The expression of IL-12 and its receptor were found in all three dental tissues. In PDL cells, the expression of IL-12R, but not IL-12, could be detected (data not shown, manuscript in preparation).

The expression of IL-12 in dental tissue might be associated with DCs, the major cell types that are responsible for IL-12 production [28]. It has been shown that, during gingivitis, DCs were resided in gingival tissues. These cells penetrated into the periodontal tissue when the disease progresses into periodontitis [6–9]. This data suggested the distribution of DCs within all of the dental soft tissues. In addition, the expression of IL-12R β_2 detected in all three dental tissues suggested the presence of IL-12 responsive cells in the healthy dental tissues.

The expression of both IL-12 and IL-12R β_2 was significantly increased in periodontal tissue isolated from inflammatory lesion (Fig. 18.1b). The upregulation of IL-12 suggested the increased number of IL-12 producing cells, possibly DCs, during periodontal inflammation. These data were in agreement with the report showing the increased number of DCs in the tissue from healthy to gingivitis and to




Fig. 18.1 The expression of IL-12 and IL-12R in dental tissues. Dental tissues, including gingiva (Gin), periodontal ligament (PDL), and dental pulp (Pulp), were obtained from patient with informed consent. Total RNA was extracted and subjected to RT-PCR analysis. The results showed all three types of tissue expressed in both IL-12 and IL-12R expression (a). The expression level of both IL-12 and IL-12R was higher in the inflammatory PDL tissue than the healthy tissue (b). IL-12 could also induce IL-12R expression in hPDL cells (c). The relative expression of IL-12R after induced with 1 ng/ml of IL-12 was shown as a graph in (d). The pictures were the representative of triplicated experiments and * indicated the statistical significance ($p < 0.05$)

periodontitis [8]. In case of IL-12R, it is possible that the upregulation of IL-12R β_2 represents the autocrine regulation of IL-12 for promoting the cellular response during periodontal inflammation.

Figure 18.1c, d showed a significant increase of IL-12R β_2 expression after IL-12 treatment in hPDL cells, supporting the concept of autocrine feedback loop. This loop has been demonstrated previously in the in vivo study reported by Thibodeaux et al. [29], showing the increased expression of both IL-12R β_1 and β_2 following the systemic administration of recombinant IL-12.

The production of IFN γ following IL-12 activation has been demonstrated to be a potent cytokine that regulated the expression of IL-12R [30]. Thus, the presence of IFN γ found in inflamed periodontal tissue (Fig. 18.1b) might enhance the expression of IL-12R during periodontal inflammation.




Fig. 18.2 IL-12-induced IFN γ expression in HPDL cells. Human PDL cells were treated with 0.5–10 ng/ml of IL-12 for 24 h. RT-PCR analysis showed the upregulation of IFN γ in a dose-dependent manner (a). The graph below showed the relative expression of IFN γ when cells were treated with 1 ng/ml of IL-12. * indicated the significant difference when compared to the control ($p < 0.05$). b showed the inductive effect of 1 ng/ml of IL-12, IL-1 β , and TNF α on the expressions of IFN γ and IL-12R. The inductive effect of IL-12 on IFN γ was inhibited by NF- κ B and STAT4 inhibitors as determined by RT-PCR (c)

18.3.2 IL-12-Mediated IFN γ Expression in hPDL Cells via STAT4 and NF- κ B Signaling Pathways

Next, we monitored the expression levels of IFN γ , a classical target of IL-12 signaling [28, 31, 32] after IL-12 treatment in hPDL cells. Figure 18.2a showed that IL-12 significantly increased IFN γ expression within 24 h. However, other destructive cytokines, including IL-1 β and TNF α , could also induce the expression of IFN γ and IL-12R (Fig. 18.2b). It is possible that the inductive effect of IL-12 might occur via other IL-12-induced cytokines. Nevertheless, both IL-1 β and TNF α could promote the response of PDL cells to IL-12 via the increased expression of IL-12R β_2 .

Normally, IL-12 signaling is generated via STAT4 [33]. In addition, STAT4-deficient mice had an identical phenotype to IL-12-deficient mice [34] supporting the role of STAT4 in IL-12 signaling pathway. However, in DCs, NF- κ B has been proposed as a major signaling molecule mediated in IL-12 activation [35]. Thus, the role of STAT4 and NF- κ B in IL-12-induced IFN γ in hPDL cells by means of inhibitors was examined. The results in Fig. 18.2c showed that both STAT4 and NF- κ B inhibitors significantly reduced the IL-12-induced IFN γ expression, suggesting the involvement of both STAT4 and NF- κ B in IL-12-induced IFN γ in hPDL cells.




Fig. 18.3 IL-12 induced the expression of IL-1 β and TNF α in hPDL cells. Human PDL cells were treated with 0.5–10 ng/ml of IL-12. The upregulation of IL-1 β (a) and TNF α (b) was detected dose dependently. Graphs on the right showed the relative expression of IL-1 β and TNF α after being treated with 1 ng/ml of IL-12 as compared to the control. * indicated the statistic difference ($p < 0.05$)

18.3.3 *IL-12-Modulated Periodontal Inflammatory Response and Immunomodulatory Property of hPDL Cells*

To investigate the modulatory effect of IL-12 on periodontal inflammatory response, the expression levels of IL-1 β and TNF α in hPDL cells following IL-12 treatment were monitored. After 24 h incubation, a significant increase in IL-1 β and TNF α mRNA expressions was detected, as shown in Fig. 18.3a, b. IL-12-induced TNF α expression was also reported in mouse BV-2 microglial cells [36]. Moreover, the study by Kim et al. [37] demonstrated the upregulation of IL-1 β following IL-12 administration in joint tissue. These evidences support the possible role of IL-12 on the enhancement of inflammatory response during periodontal disease.

Indeed, inflammatory cytokines also function as a key inducer to activate the immunomodulatory properties of mesenchymal stem cells (MSCs) [22]. In physiological condition, immunomodulatory property of MSCs is kept inactive and will be activated by inflammatory environment [22]. It is possible that during inflammation, the presence of pro-inflammatory cytokines could also serve as a potent activator to induce the immunomodulatory property of MSCs [38, 39].

The immunomodulatory properties of MSCs are the ability to express immunosuppressive molecules, such as human leukocyte antigen (HLA) [22, 23] and




Fig. 18.4 Upregulation of IDO, HLA-G, and HLA-A by IFN γ , IL-1 β , and TNF α . Human PDL cells were treated with 1 ng/ml of IFN γ , IL-1 β , and TNF α for 24 h. Real-time PCR analysis indicated that all three molecules could significantly induce the expression of IDO, HLA-G, and HLA-A. * indicated the statistical difference ($p < 0.05$)

indoleamine-pyrrole-2,3-dioxygenase (IDO) enzyme [23–25]. HLA genes are the gene encoding the major histocompatibility complex (MHC) in human. HLA functions by binding to their inhibitory receptors expressed on various types of immune cells and subsequently attenuating the immunological activation and inhibits the inflammatory response [40, 41]. IDO is a catalytic enzyme that catalyzes and degrades tryptophan, a crucial amino acid for T cell growth, leading to the inhibition of T cell proliferation [24, 42]. HPDL cells have been shown to be able to secrete IDO enzyme upon activation [43, 44]. Therefore, the upregulation of HLA-G, HLA-A, and IDO in this study may participate in the survival of PDLSCs as well as the reduction of immune responses.

The results in Fig. 18.4a–c indicated that 1 ng/ml of exogenous IFN γ , IL-1 β , and TNF α could induce IDO, HLA-G, and HLA-A as judged by real-time RT-PCR. Taken together with the results that IL-12 could induce IFN γ , IL-1 β , and TNF α , these data strongly suggested the important role of IL-12 in modulating host immune response during periodontal inflammation.

18.4 Conclusion

Our data indicated the ability of hPDL cells to respond to IL-12. The IL-12-induced IL-12R expression might be an autocrine mechanism of IL-12 to promote its cellular response in hPDL cells. IL-12 also stimulated the expression of IL-1 β and TNF α , indicated the pro-inflammatory activity of IL-12 in periodontal inflammation. Moreover, the increase in inflammatory cytokine production induced by IL-12 was demonstrated as the factors to activate the immunomodulatory property of hPDL cells, a mechanism to protect the cells from inflammatory environment. Thus, the increased level of IL-12 in periodontal inflammation may play roles in regulating periodontal tissue destruction and survival of PDL stem cells.

Acknowledgments This work was supported by Research Chair Grant 2012, the National Science and Technology Development Agency (NSTDA), Thailand. BI was supported by H.M. King Bhumipol Adulyadej's 72nd Birthday Anniversary Scholarship and Royal Golden Jubilee Scholarship from the Thailand Research Fund.

References

1. Graves DT, Oates T, Garlet GP. Review of osteoimmunology and the host response in endodontic and periodontal lesions. *J Oral Microbiol.* 2011;3:5304. doi:10.3402/jom.v3i0.5304.
2. Gelani V, Fernandes AP, Gasparoto TH, Garlet TP, Cestari TM, Lima HR, et al. The role of toll-like receptor 2 in the recognition of *Aggregatibacter actinomycetemcomitans*. *J Periodontol.* 2009;80(12):2010–9. doi:10.1902/jop.2009.090198.
3. Lima HR, Gelani V, Fernandes AP, Gasparoto TH, Torres SA, Santos CF, et al. The essential role of toll like receptor-4 in the control of *Aggregatibacter actinomycetemcomitans* infection in mice. *J Clin Periodontol.* 2010;37(3):248–54. doi:10.1111/j.1600-051X.2009.01531.x.
4. Mahanonda R, Pichyangkul S. Toll-like receptors and their role in periodontal health and disease. *Periodontology 2000.* 2007;43:41–55. doi:10.1111/j.1600-0757.2006.00179.x.
5. Williams RC, Jeffcoat MK, Kaplan ML, Goldhaber P, Johnson HG, Wechter WJ. Flurbiprofen: a potent inhibitor of alveolar bone resorption in beagles. *Science.* 1985;227(4687):640–2.
6. Cirrincione C, Pimpinelli N, Orlando L, Romagnoli P. Lamina propria dendritic cells express activation markers and contact lymphocytes in chronic periodontitis. *J Periodontol.* 2002;73(1):45–52. doi:10.1902/jop.2002.73.1.45.
7. Cutler CW, Jotwani R, Palucka KA, Davoust J, Bell D, Banchereau J. Evidence and a novel hypothesis for the role of dendritic cells and *Porphyromonas gingivalis* in adult periodontitis. *J Periodontal Res.* 1999;34(7):406–12.
8. Jotwani R, Palucka AK, Al-Quotub M, Nouri-Shirazi M, Kim J, Bell D, et al. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. *J Immunol.* 2001;167(8):4693–700.
9. Cutler CW, Jotwani R. Antigen-presentation and the role of dendritic cells in periodontitis. *Periodontol 2000.* 2004;35:135–57. doi:10.1111/j.0906-6713.2004.003560.x.
10. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by *Listeria*-induced macrophages. *Science.* 1993;260(5107):547–9.
11. Murphy EE, Terres G, Macatonia SE, Hsieh CS, Mattson J, Lanier L, et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. *J Exp Med.* 1994;180(1):223–31.

12. Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. *Immunity*. 2000;13(4):453–62.
13. Kawashima N, Stashenko P. Expression of bone-resorptive and regulatory cytokines in murine periapical inflammation. *Arch Oral Biol*. 1999;44(1):55–66.
14. Wesa AK, Galy A. IL-1 beta induces dendritic cells to produce IL-12. *Int Immunol*. 2001;13(8):1053–61.
15. Ebrahimi AA, Noshad H, Sadreddini S, Hejazi MS, Mohammadzadeh Sadigh Y, Eshraghi Y, et al. Serum levels of TNF-alpha, TNF-alphaRI, TNF-alphaRII and IL-12 in treated rheumatoid arthritis patients. *Iran J Immunol: IJL*. 2009;6(3):147–53. doi:10.1111/j.1601-0825.2011.01798.x.
16. Sanchez-Hernandez PE, Zamora-Perez AL, Fuentes-Lerma M, Robles-Gomez C, Mariaud-Schmidt RP, Guerrero-Velazquez C. IL-12 and IL-18 levels in serum and gingival tissue in aggressive and chronic periodontitis. *Oral Dis*. 2011;17(5):522–9. doi:10.1111/j.1601-0825.2011.01798.x.
17. Tsai IS, Tsai CC, Ho YP, Ho KY, Wu YM, Hung CC. Interleukin-12 and interleukin-16 in periodontal disease. *Cytokine*. 2005;31(1):34–40. doi:10.1016/j.cyto.2005.02.007.
18. Queiroz-Junior CM, Silva MJ, Correa JD, Madeira MF, Garlet TP, Garlet GP, et al. A controversial role for IL-12 in immune response and bone resorption at apical periodontal sites. *Clin Dev Immunol*. 2010;2010:327417. doi:10.1155/2010/327417.
19. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. *Nat Rev Rheumatol*. 2009;5(12):667–76. doi:10.1038/nrrheum.2009.217.
20. Leung BP, McInnes IB, Esfandiari E, Wei XQ, Liew FY. Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. *J Immunol*. 2000;164(12):6495–502.
21. Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. *Int Immunopharmacol*. 2010;10(12):1496–500. doi:10.1016/j.intimp.2010.06.019.
22. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells*. 2006;24(2):386–98. doi:10.1634/stemcells.2005-0008.
23. Noone C, Kihm A, English K, O'Dea S, Mahon BP. IFN-gamma stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. *Stem Cells Dev*. 2013;22(2):3003–14. doi:10.1089/scd.2013.0028.
24. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. *Blood*. 2004;103(12):4619–21. doi:10.1182/blood-2003-11-3909.
25. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. *Immunol Cell Biol*. 2010;88(8):795–806. doi:10.1038/icb.2010.47.
26. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. *J Exp Med*. 1999;189(7):1093–100.
27. Osathanon T, Ritprajak P, Nowwarote N, Manokawinchoke J, Giachelli C, Pavasant P. Surface-bound orientated Jagged-1 enhances osteogenic differentiation of human periodontal ligament-derived mesenchymal stem cells. *J Biomed Mater Res A*. 2013;101(2):358–67. doi:10.1002/jbm.a.34332.
28. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. *Adv Immunol*. 2001;79:55–92.
29. Thibodeaux DK, Hunter SE, Waldburger KE, Bliss JL, Trepicchio WL, Sypek JP, et al. Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells. *J Immunol*. 1999;163(10):5257–64.
30. Wu CY, Gadina M, Wang K, O'Shea J, Seder RA. Cytokine regulation of IL-12 receptor beta2 expression: differential effects on human T and NK cells. *Eur J Immunol*. 2000;30(5):1364–74.
31. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. *J Leukoc Biol*. 2004;75(2):163–89. doi:10.1189/jlb.0603252.

32. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. *J Exp Med.* 1994;180(1):211–22.
33. Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. *Proc Natl Acad Sci U S A.* 2002;99(19):12281–6. doi:[10.1073/pnas.182618999](https://doi.org/10.1073/pnas.182618999).
34. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. *Nat Rev Immunol.* 2003;3(2):133–46. doi:[10.1038/nri1001](https://doi.org/10.1038/nri1001).
35. Grohmann U, Belladonna ML, Bianchi R, Orabona C, Ayroldi E, Fioretti MC, et al. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. *Immunity.* 1998;9(3):315–23.
36. Jana M, Dasgupta S, Saha RN, Liu X, Pahan K. Induction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages. *J Neurochem.* 2003;86(2):519–28.
37. Kim HS, Chung DH. TLR4-mediated IL-12 production enhances IFN-gamma and IL-1beta production, which inhibits TGF-beta production and promotes antibody-induced joint inflammation. *Arthritis Res Ther.* 2012;14(5):R210. doi:[10.1186/ar4048](https://doi.org/10.1186/ar4048).
38. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. *Immunol Lett.* 2007;110(2):91–100. doi:[10.1016/j.imlet.2007.04.001](https://doi.org/10.1016/j.imlet.2007.04.001).
39. Li W, Ren G, Huang Y, Su J, Han Y, Li J, et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. *Cell Death Differ.* 2012;19(9):1505–13. doi:[10.1038/cdd.2012.26](https://doi.org/10.1038/cdd.2012.26).
40. Amiot L, Vu N, Samson M. Biology of the immunomodulatory molecule HLA-G in human liver diseases. *J Hepatol.* 2015;62(6):1430–7. doi:[10.1016/j.jhep.2015.03.007](https://doi.org/10.1016/j.jhep.2015.03.007).
41. Murphy B, Krensky AM. HLA-derived peptides as novel immunomodulatory therapeutics. *J Am Soc Nephrol.* 1999;10(6):1346–55.
42. Haddad R, Saldanha-Araujo F. Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far? *Biomed Res Int.* 2014;2014:216806. doi:[10.1155/2014/216806](https://doi.org/10.1155/2014/216806).
43. Moon JS, Cheong NR, Yang SY, Kim IS, Chung HJ, Jeong YW, et al. Lipopolysaccharide-induced indoleamine 2,3-dioxygenase expression in the periodontal ligament. *J Periodontal Res.* 2013;48(6):733–9. doi:[10.1111/jre.12063](https://doi.org/10.1111/jre.12063).
44. Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahim J, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet.* 2004;364(9429):149–55. doi:[10.1016/S0140-6736\(04\)16627-0](https://doi.org/10.1016/S0140-6736(04)16627-0).

Open Access This chapter is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the work's Creative Commons license, unless indicated otherwise in the credit line; if such material is not included in the work's Creative Commons license and the respective action is not permitted by statutory regulation, users will need to obtain permission from the license holder to duplicate, adapt or reproduce the material.

